Massimo Fantini

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer”.

Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00805

N/A

0DataRank · unranked

13 citations

Maria Pia Morelli, Justin M. David, Monica Neuman, Lídia Hernandez, Stephen M. Hewitt +12 more

Phase I with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.129

N/A

0DataRank · unranked

2 citations

Nicole Houston, Stan Lipkowitz, Jung Min Lee, Alexandra Dos Santos Zimmer, Farah Zia +9 more

Phase I clinical trial of NEO-201, an anti-tumor-associated CEACAM-5/6 monoclonal antibody in solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2531

N/A

0DataRank · unranked

2 citations

Maria Pia Morelli, Massimo Fantini, Marı́a M. Fergusson, Sharon Mavroukakis, Anjum Zaki +4 more

Data from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2023)10.1158/2326-6066.c.6548671.v1

N/A

0DataRank · unranked

0 citations

Caroline Jochéms, Massimo Fantini, Christopher R. Heery, James L. Gulley, Kwong Y. Tsang +2 more

Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e14515

N/A

0DataRank · unranked

0 citations

Christopher B. Cole, Ann McCoy, Massimo Fantini, Sharon Mavroukakis, Anjum Zaki +4 more

Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2530

N/A

0DataRank · unranked

2 citations

Massimo Fantini, Kwong Y. Tsang, Kevin C. Conlon, Charalampos S. Floudas, Azam Ghafoor +8 more